Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.
This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Reject Nonessential Cookies Accept All Cookies
Skip to main content
Click to go back to the Pipeline page Back To Explore Our Pipeline

Disable motion

XL102: CDK7 Inhibitor

XL102 is a selective, orally bioavailable small molecule cyclin‑dependent kinase 7 (CDK7) inhibitor, in-licensed under a collaboration agreement to supplement our drug discovery efforts.
Molecular structure shown is an artistic rendering.
XL102 is designed to inhibit CDK7, an important regulator of cell cycle progression and gene transcription, with overexpression observed in multiple cancers.
Phase 1 dose-escalation and expansion study of XL102 as single-agent and combination therapy in inoperable locally advanced or metastatic solid tumors.
Cohort Expansions
For more information, visit
This website includes information on investigational uses of compounds that have not been approved by the U.S. Food and Drug Administration (FDA). Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.
Explore All
Pipeline Clinical Trials
Click to go to Resource